09:57 AM EST, 12/19/2024 (MT Newswires) -- Omeros ( OMER ) said Thursday that its pivotal trial of narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy met its primary endpoint in overall survival.

The company said an independent analysis compared overall survival of the trial's 28 patients with

over 100 similarly high-risk patients who did not receive narsoplimab treatment, and results showed "statistically significant superiority" of overall survival data from the trial's patients.

Omeros ( OMER ) said it plans to resubmit the biologics license application for narsoplimab to the US Food and Drug Administration as soon as possible.

Shares of Omeros ( OMER ) were up over 48% in early trading.

Price: 11.08, Change: +3.62, Percent Change: +48.53